Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Kezar Life Sciences reports Q2 EPS (22c), consensus (26c) » 17:05
08/05/20
08/05
17:05
08/05/20
17:05
KZR

Kezar Life Sciences

$4.71 /

+0.07 (+1.51%)

"Our excitement…

"Our excitement continues to build around the novel mechanism of KZR-616 and supports our conviction that targeting master regulators of cellular function - like the immunoproteasome - can benefit patients in need," said John Fowler, Kezar's Chief Executive Officer. "Our recent fundraising has established a strong balance sheet to allow us to prosecute our robust pipeline."

ShowHide Related Items >><<
KZR Kezar Life Sciences
$4.71 /

+0.07 (+1.51%)

KZR Kezar Life Sciences
$4.71 /

+0.07 (+1.51%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
KZR Kezar Life Sciences
$4.71 /

+0.07 (+1.51%)

  • 09
    Jun
  • 31
    Jan
KZR Kezar Life Sciences
$4.71 /

+0.07 (+1.51%)

KZR Kezar Life Sciences
$4.71 /

+0.07 (+1.51%)

Over a month ago
Syndicate
Kezar Life Sciences 7.59M share Spot Secondary priced at $5.50 » 20:53
06/08/20
06/08
20:53
06/08/20
20:53
KZR

Kezar Life Sciences

$6.25 /

-0.62 (-9.02%)

The deal priced below the…

The deal priced below the last closing price of $6.26. Jefferies, Cowen and William Blair are acting as joint book running managers for the offering.

ShowHide Related Items >><<
KZR Kezar Life Sciences
$6.25 /

-0.62 (-9.02%)

KZR Kezar Life Sciences
$6.25 /

-0.62 (-9.02%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
KZR Kezar Life Sciences
$6.25 /

-0.62 (-9.02%)

KZR Kezar Life Sciences
$6.25 /

-0.62 (-9.02%)

KZR Kezar Life Sciences
$6.25 /

-0.62 (-9.02%)

On The Fly
Fly Intel: Pre-market Movers » 09:10
06/08/20
06/08
09:10
06/08/20
09:10
GILD

Gilead

$76.67 /

-0.85 (-1.10%)

, MGTA

Magenta Therapeutics

$9.95 /

+0.71 (+7.68%)

, FCAU

Fiat Chrysler

$10.40 /

+0.52 (+5.27%)

, THO

Thor Industries

$99.99 /

+0.97 (+0.98%)

, REVG

REV Group

$7.96 /

+0.685 (+9.42%)

, AZN

AstraZeneca

$53.87 /

+ (+0.00%)

, PCG

PG&E

$12.51 /

+0.66 (+5.57%)

, YTRA

Yatra

$1.50 /

+0.24 (+19.05%)

, KZR

Kezar Life Sciences

$6.87 /

-0.86 (-11.13%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
YTRA Yatra
$1.50 /

+0.24 (+19.05%)

THO Thor Industries
$99.99 /

+0.97 (+0.98%)

REVG REV Group
$7.96 /

+0.685 (+9.42%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

MGTA Magenta Therapeutics
$9.95 /

+0.71 (+7.68%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/08/20 Jefferies
Jefferies' Yee sees Gilead merger with AstraZeneca as unlikely
06/08/20 JPMorgan
JPMorgan sees low proability of AstraZeneca, Gilead merger
MGTA Magenta Therapeutics
$9.95 /

+0.71 (+7.68%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
THO Thor Industries
$99.99 /

+0.97 (+0.98%)

06/01/20 Monness Crespi
Camping World price target raised to $24 from $18 at Monness Crespi
04/17/20 Wolfe Research
Thor Industries initiated with an Outperform at Wolfe Research
04/14/20 KeyBanc
Thor Industries price target lowered to $62 from $69 at KeyBanc
04/08/20 Northcoast
Thor Industries, Camping World downgraded at Northcoast after RV industry checks
REVG REV Group
$7.96 /

+0.685 (+9.42%)

03/25/20 Wells Fargo
REV Group price target lowered to $4 from $10 at Wells Fargo
01/14/20 Wells Fargo
REV Group downgraded to Underweight from Equal Weight at Wells Fargo
12/16/19 Morgan Stanley
REV Group cut to Underweight on labor issues, weak RV market at Morgan Stanley
12/16/19 Morgan Stanley
REV Group downgraded to Underweight from Equal Weight at Morgan Stanley
AZN AstraZeneca
$53.87 /

+ (+0.00%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

06/05/20 BofA
PG&E resumed with a Buy at BofA
05/15/20 Barclays
Barclays upgrades Utilities sector along with PG&E and two others
05/15/20 Barclays
PG&E upgraded to Overweight from Equal Weight at Barclays
05/06/20 Mizuho
PG&E price target raised to $13.50 from $12.50 at Mizuho
YTRA Yatra
$1.50 /

+0.24 (+19.05%)

11/13/19 BMO Capital
Ebix price target lowered to $46 from $50 at BMO Capital
KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
THO Thor Industries
$99.99 /

+0.97 (+0.98%)

REVG REV Group
$7.96 /

+0.685 (+9.42%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

MGTA Magenta Therapeutics
$9.95 /

+0.71 (+7.68%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

THO Thor Industries
$99.99 /

+0.97 (+0.98%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

REVG REV Group
$7.96 /

+0.685 (+9.42%)

PCG PG&E
$12.51 /

+0.66 (+5.57%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FCAU Fiat Chrysler
$10.40 /

+0.52 (+5.27%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

Syndicate
Kezar Life Sciences files to sell common stock, no amount given » 06:16
06/08/20
06/08
06:16
06/08/20
06:16
KZR

Kezar Life Sciences

$6.87 /

-0.86 (-11.13%)

Jefferies, Cowen and…

Jefferies, Cowen and William Blair are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

KZR Kezar Life Sciences
$6.87 /

-0.86 (-11.13%)

On The Fly
Fly Intel: Pre-market Movers » 09:18
06/04/20
06/04
09:18
06/04/20
09:18
AVXL

Anavex

$3.81 /

-0.165 (-4.15%)

, KZR

Kezar Life Sciences

$4.46 /

-0.41 (-8.42%)

, NAV

Navistar

$24.84 /

+0.99 (+4.15%)

, SCWX

Secureworks

$13.86 /

+0.31 (+2.29%)

, ZUO

Zuora

$12.59 /

+0.545 (+4.53%)

, SJM

J.M. Smucker

$114.50 /

-0.69 (-0.60%)

, GIII

G-III Apparel

$13.46 /

+1.62 (+13.68%)

, MIK

Michaels

$4.60 /

+0.28 (+6.48%)

, SMAR

Smartsheet

$59.06 /

+0.745 (+1.28%)

, TWST

Twist Bioscience

$37.17 /

-1.76 (-4.52%)

, SCHW

Charles Schwab

$39.52 /

+2.385 (+6.42%)

, AMTD

TD Ameritrade

$41.36 /

+2.53 (+6.52%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

SJM J.M. Smucker
$114.50 /

-0.69 (-0.60%)

SCWX Secureworks
$13.86 /

+0.31 (+2.29%)

SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

NAV Navistar
$24.84 /

+0.99 (+4.15%)

MIK Michaels
$4.60 /

+0.28 (+6.48%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

GIII G-III Apparel
$13.46 /

+1.62 (+13.68%)

AVXL Anavex
$3.81 /

-0.165 (-4.15%)

AMTD TD Ameritrade
$41.36 /

+2.53 (+6.52%)

AVXL Anavex
$3.81 /

-0.165 (-4.15%)

03/16/20
Fly Intel: Top five analyst initiations
03/16/20 H.C. Wainwright
Anavex initiated with a Buy at H.C. Wainwright
02/27/20
Fly Intel: Top five analyst initiations
02/27/20 Cantor Fitzgerald
Anavex initiated with an Overweight and $11 target at Cantor Fitzgerald
KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

06/04/20 H.C. Wainwright
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright
05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
NAV Navistar
$24.84 /

+0.99 (+4.15%)

06/02/20 Longbow
Navistar downgraded to Neutral from Buy at Longbow
05/07/20 Longbow
Navistar likely to beat near-term expectations, says Longbow
04/17/20 JPMorgan
Truck cancellation rate in March hits high at 43%, says JPMorgan
04/03/20 JPMorgan
Class 8 truck orders dropped 51% in March, says JPMorgan
SCWX Secureworks
$13.86 /

+0.31 (+2.29%)

03/20/20 Goldman Sachs
Secureworks upgraded to Neutral from Sell at Goldman Sachs
11/12/19 Goldman Sachs
Secureworks initiated with a Sell at Goldman Sachs
ZUO Zuora
$12.59 /

+0.545 (+4.53%)

06/04/20 Canaccord
Zuora price target raised to $19 from $15 at Canaccord
06/04/20 Jefferies
Zuora price target raised to $15 from $11 at Jefferies
05/22/20 Canaccord
Zuora assumed with a Buyinitiated with a Buy at Canaccord
05/14/20 Jefferies
Zuora downgraded to Hold from Buy at Jefferies
SJM J.M. Smucker
$114.50 /

-0.69 (-0.60%)

04/21/20 Deutsche Bank
J.M. Smucker price target raised to $124 from $110 at Deutsche Bank
04/16/20
Fly Intel: Top five analyst upgrades
04/16/20 Credit Suisse
J.M. Smucker upgraded to Neutral from Underperform at Credit Suisse
03/18/20 Credit Suisse
J.M. Smucker price target raised to $115 from $100 at Credit Suisse
GIII G-III Apparel
$13.46 /

+1.62 (+13.68%)

03/24/20 Cowen
G-III Apparel downgraded to Market Perform at Cowen
03/24/20 Cowen
G-III Apparel downgraded to Market Perform from Outperform at Cowen
01/02/20
Fly Intel: Top five analyst upgrades
01/02/20 Wells Fargo
G-III Apparel upgraded to Overweight from Equal Weight at Wells Fargo
MIK Michaels
$4.60 /

+0.28 (+6.48%)

03/18/20
Fly Intel: Top five analyst downgrades
03/18/20 Credit Suisse
Michaels price target lowered to $4 from $11 at Credit Suisse
03/18/20 Guggenheim
Michaels downgraded to Neutral from Buy at Guggenheim
01/16/20
Fly Intel: Top five analyst downgrades
SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

06/04/20 Stephens
Stephens would be buyer of Smartsheet amid pullback
06/04/20 Needham
Smartsheet price target raised to $70 from $60 at Needham
06/04/20 Canaccord
Smartsheet price target raised to $55 from $45 at Canaccord
06/04/20 Wedbush
Smartsheet price target raised to $45 from $40 at Wedbush
TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
05/20/20 Compass Point
Charles Schwab downgraded to Neutral at Compass Point as low rates limit growth
05/20/20 Compass Point
TD Ameritrade downgraded to Neutral on rate headwinds at Compass Point
AMTD TD Ameritrade
$41.36 /

+2.53 (+6.52%)

05/20/20 Compass Point
TD Ameritrade downgraded to Neutral from Buy at Compass Point
04/27/20 Citi
TD Ameritrade downgraded to Neutral from Buy at Citi
ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

SJM J.M. Smucker
$114.50 /

-0.69 (-0.60%)

SCWX Secureworks
$13.86 /

+0.31 (+2.29%)

SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

NAV Navistar
$24.84 /

+0.99 (+4.15%)

MIK Michaels
$4.60 /

+0.28 (+6.48%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

GIII G-III Apparel
$13.46 /

+1.62 (+13.68%)

AVXL Anavex
$3.81 /

-0.165 (-4.15%)

AMTD TD Ameritrade
$41.36 /

+2.53 (+6.52%)

  • 04
    Jun
SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

SJM J.M. Smucker
$114.50 /

-0.69 (-0.60%)

SCWX Secureworks
$13.86 /

+0.31 (+2.29%)

SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

NAV Navistar
$24.84 /

+0.99 (+4.15%)

ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

SJM J.M. Smucker
$114.50 /

-0.69 (-0.60%)

SCWX Secureworks
$13.86 /

+0.31 (+2.29%)

SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

NAV Navistar
$24.84 /

+0.99 (+4.15%)

MIK Michaels
$4.60 /

+0.28 (+6.48%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

GIII G-III Apparel
$13.46 /

+1.62 (+13.68%)

AMTD TD Ameritrade
$41.36 /

+2.53 (+6.52%)

ZUO Zuora
$12.59 /

+0.545 (+4.53%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

SCHW Charles Schwab
$39.52 /

+2.385 (+6.42%)

MIK Michaels
$4.60 /

+0.28 (+6.48%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

AVXL Anavex
$3.81 /

-0.165 (-4.15%)

Recommendations
Kezar Life Sciences price target raised to $12 from $9 at H.C. Wainwright » 06:16
06/04/20
06/04
06:16
06/04/20
06:16
KZR

Kezar Life Sciences

$4.46 /

-0.41 (-8.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Kezar Life Sciences to $12 from $9 and reiterates a Buy rating on the shares after the company reported interim data from the Phase 1b portion of the MISSION trial testing its most advanced candidate, KZR-616. Improvements were seen across seven measures of disease activity, and two out of two patients with lupus nephritis experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity, Selvaraju tells investors in a research note.

ShowHide Related Items >><<
KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

On The Fly
Fly Intel: After-Hours Movers » 18:32
06/03/20
06/03
18:32
06/03/20
18:32
ZUO

Zuora

$12.59 /

+0.545 (+4.53%)

, TLYS

Tilly's

$6.31 /

+0.31 (+5.17%)

, GWRE

Guidewire

$110.35 /

+3.635 (+3.41%)

, GEF

Greif

$36.15 /

+2.32 (+6.86%)

, KZR

Kezar Life Sciences

$4.46 /

-0.41 (-8.42%)

, ATSG

Air Transport Services

$21.15 /

-0.57 (-2.62%)

, FIT

Fitbit

$6.25 /

-0.035 (-0.56%)

, COST

Costco

$306.70 /

-0.38 (-0.12%)

, SMAR

Smartsheet

$59.06 /

+0.745 (+1.28%)

, CLDR

Cloudera

$12.40 /

+1.15 (+10.22%)

, CMTL

Comtech

$20.99 /

+2.51 (+13.58%)

, ESTC

Elastic

$89.23 /

+0.41 (+0.46%)

, FOSL

Fossil

$3.81 /

+0.375 (+10.93%)

, NMIH

NMI Holdings

$16.86 /

+0.87 (+5.44%)

, TWST

Twist Bioscience

$37.17 /

-1.76 (-4.52%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

TLYS Tilly's
$6.31 /

+0.31 (+5.17%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

NMIH NMI Holdings
$16.86 /

+0.87 (+5.44%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

GWRE Guidewire
$110.35 /

+3.635 (+3.41%)

GEF Greif
$36.15 /

+2.32 (+6.86%)

FOSL Fossil
$3.81 /

+0.375 (+10.93%)

FIT Fitbit
$6.25 /

-0.035 (-0.56%)

ESTC Elastic
$89.23 /

+0.41 (+0.46%)

COST Costco
$306.70 /

-0.38 (-0.12%)

CMTL Comtech
$20.99 /

+2.51 (+13.58%)

CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

ATSG Air Transport Services
$21.15 /

-0.57 (-2.62%)

ZUO Zuora
$12.59 /

+0.545 (+4.53%)

05/22/20 Canaccord
Zuora assumed with a Buyinitiated with a Buy at Canaccord
05/14/20 Jefferies
Zuora downgraded to Hold from Buy at Jefferies
04/14/20 Morgan Stanley
Morgan Stanley sees pause in 'subscription economy,' cuts Zuora to Underweight
04/14/20 Morgan Stanley
Zuora downgraded to Underweight from Equal Weight at Morgan Stanley
TLYS Tilly's
$6.31 /

+0.31 (+5.17%)

01/14/20 Pivotal Research
Tilly's downgraded to Hold from Buy at Pivotal Research
01/14/20 Pivotal Research
Tilly's downgraded to Hold from Buy at Pivotal Research
01/13/20 Roth Capital
Tilly's holiday results 'disappointing,' says Roth Capital
GWRE Guidewire
$110.35 /

+3.635 (+3.41%)

04/29/20 Baird
Guidewire downgraded to Neutral at Baird
04/29/20 Baird
Guidewire downgraded to Neutral from Outperform at Baird
04/17/20 Guggenheim
Guidewire downgraded to Neutral from Buy at Guggenheim
04/16/20 BTIG
Guidewire initiated with a Buy at BTIG
GEF Greif
$36.15 /

+2.32 (+6.86%)

03/02/20 BMO Capital
Greif price target lowered to $32 from $36 at BMO Capital
02/13/20 BofA
Paused project a positive for containerboard market, says BofA
01/14/20
Fly Intel: Top five analyst upgrades
01/14/20 Wells Fargo
Greif upgraded to Overweight from Equal Weight at Wells Fargo
KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
ATSG Air Transport Services
$21.15 /

-0.57 (-2.62%)

05/01/20 Truist
Air Transport Services initiated with a Buy at SunTrust
05/01/20 Truist
Air Transport Services initiated with a Buy at SunTrust
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Loop Capital
Air Transport Services initiated with a Hold at Loop Capital
FIT Fitbit
$6.25 /

-0.035 (-0.56%)

11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
11/04/19 Citi
Fitbit upgraded to Neutral from Sell at Citi
COST Costco
$306.70 /

-0.38 (-0.12%)

05/29/20 Baird
Costco improved comps seen likely for May, says Baird
05/29/20 RBC Capital
Costco price target raised to $348 from $332 at RBC Capital
05/06/20 Baird
Costco SSS decline due to pressure from temporal factors, says Baird
04/15/20 Citi
Costco assumed with a Neutral at Citi
SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

05/15/20 Citi
Smartsheet initiated with a Neutral at Citi
05/14/20 Jefferies
Smartsheet downgraded to Hold from Buy at Jefferies
04/23/20 JPMorgan
Smartsheet downgraded to Neutral with $50 target at JPMorgan
04/23/20 JPMorgan
Smartsheet downgraded to Neutral from Overweight at JPMorgan
CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

06/03/20
Fly Intel: Top five analyst upgrades
06/03/20 Morgan Stanley
Morgan Stanley upgrades Cloudera to Overweight on stabilization, upcoming growth
06/03/20 Morgan Stanley
Cloudera upgraded to Overweight from Equal Weight at Morgan Stanley
04/07/20 Craig-Hallum
IBM could be 'a logical' acquirer of Cloudera, says Craig-Hallum
CMTL Comtech
$20.99 /

+2.51 (+13.58%)

03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
ESTC Elastic
$89.23 /

+0.41 (+0.46%)

06/01/20 RBC Capital
Elastic price target raised to $95 from $85 at RBC Capital
04/16/20
DA Davidson starts Elastic with a Buy on significant growth potential
04/15/20 DA Davidson
Elastic initiated with a Buy at DA Davidson
03/24/20 Oppenheimer
Elastic price target lowered to $90 from $110 at Oppenheimer
FOSL Fossil
$3.81 /

+0.375 (+10.93%)

11/07/19 KeyBanc
Fossil turnaround 'has not manifested,' says KeyBanc
11/07/19 KeyBanc
Fossil downgraded to Sector Weight from Overweight at KeyBanc
NMIH NMI Holdings
$16.86 /

+0.87 (+5.44%)

06/01/20 B. Riley FBR
B. Riley FBR upgrades Radian on better forbearance data trends
04/06/20 B. Riley FBR
Fannie, Freddie downgraded to Sell with $1 targets at B. Riley FBR
03/26/20 RBC Capital
NMI Holdings price target lowered to $18 from $38 at RBC Capital
03/11/20 B. Riley FBR
B. Riley FBR downgrades CNO Financial, Progressive to Neutral from Buy
TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

TLYS Tilly's
$6.31 /

+0.31 (+5.17%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

NMIH NMI Holdings
$16.86 /

+0.87 (+5.44%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

GWRE Guidewire
$110.35 /

+3.635 (+3.41%)

GEF Greif
$36.15 /

+2.32 (+6.86%)

FOSL Fossil
$3.81 /

+0.375 (+10.93%)

FIT Fitbit
$6.25 /

-0.035 (-0.56%)

ESTC Elastic
$89.23 /

+0.41 (+0.46%)

COST Costco
$306.70 /

-0.38 (-0.12%)

CMTL Comtech
$20.99 /

+2.51 (+13.58%)

CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

ATSG Air Transport Services
$21.15 /

-0.57 (-2.62%)

  • 04
    Jun
  • 04
    Jun
SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

FIT Fitbit
$6.25 /

-0.035 (-0.56%)

COST Costco
$306.70 /

-0.38 (-0.12%)

CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

ZUO Zuora
$12.59 /

+0.545 (+4.53%)

TWST Twist Bioscience
$37.17 /

-1.76 (-4.52%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

FIT Fitbit
$6.25 /

-0.035 (-0.56%)

ESTC Elastic
$89.23 /

+0.41 (+0.46%)

COST Costco
$306.70 /

-0.38 (-0.12%)

CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

ZUO Zuora
$12.59 /

+0.545 (+4.53%)

SMAR Smartsheet
$59.06 /

+0.745 (+1.28%)

KZR Kezar Life Sciences
$4.46 /

-0.41 (-8.42%)

FOSL Fossil
$3.81 /

+0.375 (+10.93%)

FIT Fitbit
$6.25 /

-0.035 (-0.56%)

ESTC Elastic
$89.23 /

+0.41 (+0.46%)

COST Costco
$306.70 /

-0.38 (-0.12%)

CLDR Cloudera
$12.40 /

+1.15 (+10.22%)

Hot Stocks
Kezar Life Sciences announces updated results from portion of MISSION trial » 16:06
06/03/20
06/03
16:06
06/03/20
16:06
KZR

Kezar Life Sciences

$4.50 /

-0.37 (-7.60%)

Kezar Life Sciences…

Kezar Life Sciences announced updated results from the Phase 1b portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus, or SLE, with and without nephritis. Overall, improvements were seen across seven measures of disease activity, and two of two patients with lupus nephritis, or LN, experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity. A "positive" safety and tolerability profile was observed with step-up dosing of KZR-616. The Phase 1b dataset builds on the safety and tolerability testing performed in 100 healthy subjects from two Phase 1a studies. As of the May 4 data cutoff, the Ph1b portion of MISSION enrolled 39 SLE patients across five dose cohorts evaluating 45 mg and step-up dosing to 60 mg weekly for 13 weeks. Patients are followed to week 25 and kept on stable background treatment. Below are the results for step-up dosing Cohorts 2a, 2b, and 2c, which enrolled 26 patients. At this time point, a total of 16 patients from these cohorts completed 13 weeks of treatment and are included in the exploratory efficacy measures reported below. Two SLE patients with biopsy-proven lupus nephritis were included in the Phase 1b portion. Both patients showed a greater than 50% reduction in proteinuria as measured by urine protein to creatine ratio, as well as reductions in SLEDAI and reductions in anti-dsDNA antibody levels. Among patients completing treatment in Cohorts 2a and 2b, all seven measures of disease activity improved in the majority of patients from Baseline to Week 13. Improvement in disease activity persisted following the end-of-treatment. Step-up dosing of KZR-616 improved overall tolerability. Most treatment emergent adverse events, or TEAEs, occurred early and diminished with later doses. To date, no patients have discontinued treatment in Cohorts 2b and 2c, which utilize a lyophilized formulation of KZR-616. The most common treatment emergent adverse events were transient injection site reactions.

ShowHide Related Items >><<
KZR Kezar Life Sciences
$4.50 /

-0.37 (-7.60%)

KZR Kezar Life Sciences
$4.50 /

-0.37 (-7.60%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
KZR Kezar Life Sciences
$4.50 /

-0.37 (-7.60%)

KZR Kezar Life Sciences
$4.50 /

-0.37 (-7.60%)

KZR Kezar Life Sciences
$4.50 /

-0.37 (-7.60%)

Options
Thirteen new option listings and four option delistings on May 28th » 08:30
05/28/20
05/28
08:30
05/28/20
08:30
CFRX

ContraFect

$5.35 /

-0.045 (-0.83%)

, FREQ

Frequency Therapeutics

$18.27 /

+0.8 (+4.58%)

, HARP

Harpoon Therapeutics

$21.77 /

-3.23 (-12.92%)

, HOOK

Hookipa Pharma

$11.23 /

+0.73 (+6.95%)

, HSTO

Histogen

$4.61 /

+4.054 (+729.14%)

, IFRX

InflaRx

$8.36 /

+0.2 (+2.45%)

, KNSA

Kiniksa

$20.86 /

-0.89 (-4.09%)

, KZR

Kezar Life Sciences

$5.30 /

+0.05 (+0.95%)

, LQDA

Liquidia Technologies

$9.03 /

+0.05 (+0.56%)

, OVID

Ovid Therapeutics

$5.71 /

-0.97 (-14.52%)

, PRVL

Prevail Therapeutics

$16.83 /

-0.38 (-2.21%)

, CNAT

Conatus

$0.00 /

+ (+0.00%)

, CORV

Correvio

$0.42 /

+ (+0.00%)

, CTRC

Centric Brands

$0.19 /

-0.0279 (-12.65%)

, UNT

Unit Corp.

/

+

New option listings for…

New option listings for May 28th include ContraFect (CFRX), Centric Brands Inc (CTRCQ), Frequency Therapeutics Inc (FREQ), Harpoon Therapeutics Inc (HARP), HOOKIPA Pharma Inc (HOOK), Histogen Inc (HSTO), InflaRx NV (IFRX), Kiniksa Pharmaceuticals Ltd (Class A Stock) (KNSA), Kezar Life Sciences Inc (KZR), Liquidia Technologies Inc (LQDA), Ovid Therapeutics (OVID), Prevail Therapeutics Inc (PRVL), and Unit Corp (UNTCQ). Option delistings effective May 28th include Conatus Pharmaceuticals Inc (CNAT), Correvio Pharma Corporation (CORV), Centric Brands Inc (CTRC), and Unit Corp (UNT).

ShowHide Related Items >><<
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HSTO Histogen
$4.61 /

+4.054 (+729.14%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CORV Correvio
$0.42 /

+ (+0.00%)

CNAT Conatus
$0.00 /

+ (+0.00%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 Truist
Harpoon Therapeutics initiated with a Buy at SunTrust
HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
HSTO Histogen
$4.61 /

+4.054 (+729.14%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

05/21/20 BMO Capital
InflaRx price target raised to $7 from $4 at BMO Capital
05/21/20 Raymond James
Raymond James doubles InflaRx price target to $20 ahead of COVID data
05/21/20 Raymond James
InflaRx price target raised to $20 from $10 at Raymond James
04/30/20 Raymond James
InflaRx upgraded to Outperform from Market Perform at Raymond James
KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
04/27/20 Piper Sandler
Prevail 20% pullback brings 'unique' buying opportunity, says Piper Sandler
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Piper Sandler
Prevail Therapeutics initiated with an Overweight at Piper Sandler
CNAT Conatus
$0.00 /

+ (+0.00%)

CORV Correvio
$0.42 /

+ (+0.00%)

12/11/19 H.C. Wainwright
Correvio downgraded to Neutral from Buy at H.C. Wainwright
09/03/19 Cantor Fitzgerald
Correvio initiated with an Overweight at Cantor Fitzgerald
CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

UNT Unit Corp.
/

+

03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Unit Corp. downgraded to Underweight from Equal Weight at Stephens
01/06/20 Raymond James
Unit Corp. downgraded at Raymond James on commodity price weakness
01/06/20 Raymond James
Unit Corp. downgraded to Underperform from Market Perform at Raymond James
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

Over a quarter ago
Earnings
Kezar Life Sciences reports Q1 EPS (30c), consensus (38c) » 16:14
05/07/20
05/07
16:14
05/07/20
16:14
KZR

Kezar Life Sciences

$6.08 /

+0.88 (+16.92%)

"During this…

"During this unprecedented health crisis, I've been deeply impressed by our team's focus and continued execution across both of our programs," said John Fowler, Kezar's Chief Executive Officer. "We are working closely with all the sites participating in our trials with KZR-616 and look forward to sharing new data from the Phase 1b portion of our MISSION study next month. In addition, we will present more preclinical data on our novel protein secretion inhibitor, KZR-261, in an e-poster during ASCO 2020 and remain on track for an IND submission in the first quarter of 2021." Cash, cash equivalents and marketable securities totaled $123.4 million as of March 31, 2020, compared to $78.2 million as of December 31, 2019. The increase in cash, cash equivalents and marketable securities was primarily attributable to the net proceeds from the underwritten public offering in February 2020, net of cash used by the Company in operations to advance its clinical stage programs and preclinical research and development. The Company believes that its current cash, cash equivalent and marketable securities are sufficient to fund planned operations into the third quarter of 2022.

ShowHide Related Items >><<
KZR Kezar Life Sciences
$6.08 /

+0.88 (+16.92%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.